Peter Armstrong Thompson

Bio: Peter Armstrong Thompson is an academic researcher. The author has contributed to research in topics: Fusion protein & Binding domain. The author has an hindex of 8, co-authored 24 publications receiving 661 citations.

Single-chain multivalent binding proteins with effector function

Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.

CD86 antagonist multi-target binding proteins

Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

B-cell reduction using cd37-specific and cd20-specific binding molecules

Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Tumor targeting conjugates and methods of use thereof

Abstract: Various compositions are disclosed. The compositions of conjugates comprising immune-stimulatory compounds are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating disorders, such as cancer.

Simultaneous inhibition of pd-l1/pd-l2

Abstract: Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

Bivalent, bispecific antibodies

Abstract: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.

Treatment of cancer using humanized anti-cd19 chimeric antigen receptor

Abstract: The disclosure provides compositions and methods for treating diseases associated with expression of CD19. The disclosure also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.

Method of error correction for 3D imaging device

Abstract: A method is presented for correcting errors in a 3D scanner. Measurement errors in the 3D scanner are determined by scanning each of a plurality of calibration objects in each of a plurality of sectors in the 3D scanner's field of view. The calibration objects have a known height, a known width, and a known length. The measurements taken by the 3D scanner are compared to the known dimensions to derive a measurement error for each dimension in each sector. An estimated measurement error is calculated based on scans of each of the plurality of calibration objects. When scanning target objects in a given sector, the estimated measurement error for that sector is used to correct measurements obtained by the 3D scanner.

Antibody molecules to pd-1 and uses thereof

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.